English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Tools annual

Global: Zendy Free Plan

Global: Zendy Tools monthly

Global: Zendy Plus monthly

Currently available platelet function assays largely ignore the important characteristics of  in vivo  thrombus generation, such as flow conditions and shear. The AggreGuide A−100 ADP Assay detects platelet aggregation in whole blood using light scattering under flow conditions. In this review article, we discuss the limitations of currently available platelet function assays and the technology underlying the AggreGuide A−100 ADP assay. We also discuss the results of the validation assay study. By incorporating arterial flow conditions and shear, the AggreGuide assay may be more indicative of  in vivo  thrombus generation as compared to currently available platelet function assays. As per the United States, Food and Drug administration, the AggreGuide A−100 ADP test has been cleared to assess antiplatelet effects of prasugrel and ticagrelor. The assay results are comparable to widely used VerifyNow PRU assay. The utility of AggreGuide A100-ADP Assay in guiding P2Y12 receptor inhibitor therapy in patients with cardiovascular disease needs to be explored in clinical studies.

An evaluation of the AggreGuide A-100 ADP Assay for measuring the effect of antiplatelet agents targeting the P2Y 12 receptor